|
|
Article: Santaris Signs $200M LNA Oncology Pact With Enzon.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioWorld International Correspondent
Santaris Pharma A/S gained commercial validation for its Locked Nucleic Acid (LNA) oligonucleotide analogue chemistry through a co-development and commercialization oncology deal with Enzon Pharmaceuticals Inc., which is worth well in excess of $200 million in up-front fees and milestone payments.
Bridgewater, N.J.-based Enzon is licensing two preclinical LNA-based drug candidates from Santaris: SPC2968, an antagonist to hypoxia inducible factor-1alpha (HIF-1alpha); and an antagonist to the anti-apoptosis protein Survivin, called SPC3042. In addition, it is generating six more LNAs to oncology targets specified by ...